Quarterly ResultMay 12, 2026, 04:38 PM
LB Pharmaceuticals Q1 Net Loss $(19.1)M; Initiates Phase 2/3 Trials
AI Summary
LB Pharmaceuticals reported a net loss of $19.1 million for Q1 2026, an increase from $5.3 million in Q1 2025, driven by significantly higher research and development expenses. The company successfully completed a private placement in February 2026, raising $93.8 million in net proceeds, bolstering its cash position to $365.6 million. During the quarter, LB Pharmaceuticals initiated Phase 2 and Phase 3 clinical trials for its lead product candidate, LB-102, for bipolar 1 depression and acute schizophrenia, respectively.
Key Highlights
- Net proceeds of $93.8 million from a private placement completed in February 2026.
- Q1 2026 net loss increased to $(19.1) million from $(5.3) million in Q1 2025.
- Research and development expenses rose to $14.6 million in Q1 2026 from $3.4 million in Q1 2025.
- General and administrative expenses increased to $7.5 million in Q1 2026 from $3.0 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $365.6 million as of March 31, 2026.
- Initiated Phase 2 clinical trial (ILLUMINATE-1) for LB-102 in bipolar 1 depression.
- Initiated Phase 3 clinical trial (NOVA-2) for LB-102 in acute schizophrenia.
- Current capital resources are expected to fund operations for at least the next twelve months.
Price Impact
More from LBRX